A Study of JNJ-89862175 for Advanced Solid Tumors
This study is testing a drug called JNJ-89862175 for people with advanced solid tumors, specifically lung adenocarcinoma, certain kidney cancers (renal cell carcinoma: clear cell or papillary), and certain ovarian or uterine cancers (endometrioid ovarian cancer and endometrioid uterine carcinoma). The main goal is to find a safe and effective dose of JNJ-89862175. Researchers will first look at how many participants experience dose-limiting toxicities (side effects that are severe enough to stop or delay treatment) and other side effects. Once a safe dose is found, they will further evaluate its safety. You may be able to join if you are 18 or older, have one of these advanced solid tumors, and meet other health criteria. The study plans to enroll about 360 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive JNJ-89862175. It is designed in two parts: first to find a safe dose, and then to further evaluate safety at that dose.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for adverse events (side effects) for up to 2 years and 10 months after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
At a glance
Conditions
Where it's being run
6 sites across 4 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)Up to 21 days
The DLTs are specific adverse events that includes high grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation.
- Part 1: Number of Participants with Adverse Events (AEs) by SeverityUp to 2 years and 10 months
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
- Part 2: Number of Participants with Adverse Events (AEs) by Severity at RP2DUp to 2 years and 10 months
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.